Best Ketamine Therapy for Anxiety: Options Compared

What Is Ketamine Therapy for Anxiety?

Ketamine therapy uses sub-anesthetic doses of ketamine, prescribed by a licensed provider, to treat mental health conditions. Ketamine has been an FDA-approved anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985. Prescribing it for depression or anxiety is off-label, which is a widespread and legally accepted practice in psychiatry.

For anxiety specifically, ketamine therapy is most commonly used to treat generalized anxiety disorder (GAD) and social anxiety disorder (SAD).⁴,⁹ Because anxiety is often comorbid with depression, most published ketamine research measures depression (using the PHQ-9 questionnaire) and anxiety (using the GAD-7 questionnaire) on the same patients across the same course of treatment.¹,² Other anxiety-spectrum diagnoses, including post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and panic disorder, are separate DSM-5 categories with their own clinical literature; this article focuses on the GAD and SAD evidence base.

Within ketamine therapy, the term covers protocols that look very different from each other. The published research divides into three categories.

• ‍Therapeutic-dose at-home ketamine therapy. Sub-anesthetic but perceptually active doses of racemic ketamine, prescribed by a licensed provider, self-administered sublingually at home as part of structured, periodic treatment sessions across a multi-week protocol.¹,² This is the model used by Mindbloom and similar at-home programs.‍
• Therapeutic-dose in-clinic ketamine therapy. Sub-anesthetic but perceptually active doses administered in a medical setting under direct clinical supervision, either as an IV infusion of racemic ketamine (used by IV ketamine clinics)⁵,⁶ or as intranasal esketamine (Spravato), administered in REMS-certified healthcare settings.¹¹‍
• Daily low-dose ketamine. Sub-perceptual oral doses of ketamine prescribed for daily self-administration without a structured treatment session built around each dose. This is a structurally different model from the two above and is marketed by some at-home providers as a daily medication regimen.³

How Effective Is At-Home Ketamine Therapy for Anxiety?

At-home ketamine therapy uses sublingual racemic ketamine, prescribed by a licensed provider after a clinical screening and intake process, self-administered by the patient in a structured treatment session at home. Sessions are typically held on a periodic schedule (often once per week across a four-to-six-week core treatment course), with each session bookended by preparation activities and a settling period afterward. The dose is therapeutic, meaning it is large enough to produce perceptual changes that are considered part of the treatment mechanism, rather than sub-perceptual.

Two peer-reviewed real-world effectiveness studies of Mindbloom's at-home sublingual ketamine therapy program (Hull 2022, Mathai 2024) have published anxiety outcomes on a combined total of more than 8,700 patients with structured baseline GAD-7 measurements.¹,² Across both studies, mean GAD-7 scores fell by roughly half after a four-week course, response rates ranged from 56% to 63%, and remission rates ranged from 29% to 31%. The full numbers from each study are laid out under "Mindbloom Outcomes for Anxiety" below.

The result: when the question is at-home therapeutic-dose ketamine therapy for anxiety, the published evidence is substantial in scale, prospective in design, and consistent across two independent peer-reviewed studies.

How Effective Is Daily Low-Dose Ketamine for Anxiety?

Daily low-dose ketamine is marketed by some at-home ketamine providers as an alternative model in which low oral doses are taken daily, without a structured treatment session built around each dose. Some of those providers market the protocol as a treatment for anxiety.

Based on the peer-reviewed literature available as of publication, no prospective clinical trial of any daily low-dose ketamine protocol has examined an anxiety disorder as a primary outcome in any patient population. The closest study in the daily low-dose literature is Irwin et al. 2013, a 28-day open-label trial of once-daily oral racemic ketamine in 14 hospice patients with advanced or terminal illness.³ That trial measured depression and global symptom burden, not anxiety as a stand-alone outcome on a validated anxiety-specific instrument like the GAD-7. It also enrolled a population (terminal hospice) that does not generalize to the general outpatient population to whom daily low-dose ketamine is currently marketed.

In other words: the daily low-dose ketamine therapy that some providers market as a treatment for anxiety has not been shown to work for anxiety. It also has not been shown not to work. The peer-reviewed studies that would answer the question have not been done.

How Effective Is In-Clinic Ketamine Therapy for Anxiety?

In-clinic ketamine therapy for anxiety covers two distinct protocols. The first is IV ketamine, administered as an infusion in a clinical setting, typically by an anesthesiologist or psychiatric provider. The second is intranasal esketamine (Spravato), administered under REMS-certified supervision in a healthcare facility.¹¹ Both have been studied in the published literature for depression. Whether they have been studied for anxiety has a more complicated answer.

Is IV Ketamine Effective for Anxiety?

The published research on IV ketamine for anxiety comes almost entirely from small academic studies, not from real-world IV ketamine clinics. The most comprehensive systematic review of the literature (Whittaker et al. 2021) identified only two randomized controlled trials of ketamine in social anxiety disorder, with a combined enrollment of 30 patients, and zero trials in generalized anxiety disorder.⁴ The largest published real-world effectiveness study of an IV ketamine clinic (McInnes et al. 2022, n=537) measured depression outcomes only; anxiety was not a reported outcome.⁵ Based on the peer-reviewed literature available as of publication, no comparable at-scale real-world effectiveness study of IV ketamine for anxiety has been published from any IV ketamine clinic.

The small academic studies that do exist report favorable acute response.

• Taylor et al. 2018 randomized 18 adults with DSM-5 social anxiety disorder to a single IV dose of ketamine (0.5 mg/kg) or placebo in a crossover trial.⁶ Response on the Liebowitz Social Anxiety Scale (defined as ≥35% reduction) was 33.3% on ketamine versus 0% on placebo. The measurement window was within 2 weeks of the infusion.
• Glue et al. 2017 enrolled 12 patients with treatment-refractory generalized or social anxiety disorder in an open-label ascending single-dose subcutaneous ketamine pilot.⁷ At doses of 0.5 to 1 mg/kg, 8 of 12 patients (67%) had a greater than 50% reduction on the Hamilton Anxiety Rating Scale or Fear Questionnaire.
• Glue et al. 2018, a 3-month open-label maintenance pilot from the same research group, enrolled 20 patients with generalized or social anxiety disorder on weekly subcutaneous ketamine (1 mg/kg).⁸ Anxiety scores on the Hamilton Anxiety Rating Scale and Fear Questionnaire decreased approximately 50% at 1 hour post-dose, with 18 of 20 patients reporting improved social or work functioning.

These are the most commonly cited controlled and semi-controlled studies of IV or injectable ketamine for generalized and social anxiety disorders in the peer-reviewed literature available as of publication. Their combined enrollment is 50 patients.

A note on those response rates: they describe different things from the at-home numbers. Glue 2018 measured response at 1 hour post-injection.⁸ Taylor 2018 measured response within two weeks of a single infusion.⁶ The at-home effectiveness data was measured at session 4, after the acute effect of any individual dose had worn off.¹,² Acute response and end-of-course response are both real findings, but they aren't interchangeable.

Is Spravato Effective for Anxiety?

Spravato (intranasal esketamine) is not FDA-approved for any anxiety disorder. Janssen, the manufacturer, has not sought anxiety approval and has not yet run an anxiety-primary clinical trial.¹¹ Reviews of the ketamine and esketamine anxiety literature have consistently reached the same conclusion: no esketamine clinical trial has examined an anxiety disorder as a primary indication.⁴,⁹,¹⁰ The product is FDA-approved for treatment-resistant depression (2019) and for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior (2020), both depression indications.¹¹

There is also a practical access dimension worth understanding. Spravato can only be administered in REMS-certified healthcare settings under the FDA's Risk Evaluation and Mitigation Strategy program, which restricts who can prescribe and dispense the product and requires a qualifying depression diagnosis for eligibility.¹¹ In other words, there is no FDA-recognized clinical pathway to access Spravato as a stand-alone treatment for an anxiety disorder. A patient seeking Spravato specifically for anxiety would not be a candidate for it under the labeled indication.

How These Ketamine Therapy Options Compare for Anxiety

The three categories differ not only in active medication and delivery method, but in what has been measured, who was studied, how outcomes were assessed, and how each model is administered. The table below summarizes the published anxiety evidence base for each category. Comparisons across these studies should be made carefully, because they used different anxiety instruments, different patient populations, different dosing schedules, and different measurement windows.

In addition to clinical outcomes, several other dimensions matter when choosing between options.

Care Model and Support Structure

At-home ketamine therapy programs typically combine clinical screening with a licensed prescriber, a structured intake process, scheduled treatment sessions self-administered at home, and ongoing access to clinical support throughout the treatment course.¹,² In-clinic ketamine therapy is administered directly by a healthcare provider in a clinical setting, with monitoring during and immediately after each dose. Spravato administration must take place in a REMS-certified healthcare facility with on-site post-dose monitoring.¹¹ Daily low-dose protocols generally involve an initial telehealth evaluation followed by a daily medication routine without a structured per-dose support framework.

Administration and Schedule

At-home therapeutic-dose protocols use sublingual racemic ketamine in periodic structured sessions, typically once per week during the core treatment course.¹,² IV ketamine is delivered as an infusion at a clinic on a schedule set by the prescriber, commonly twice per week during induction and tapered thereafter.⁵ Spravato is delivered intranasally on a clinic-administered schedule.¹¹ Daily low-dose protocols use oral ketamine taken daily by the patient without a structured session around each dose.

Safety Protocols and Screening

All ketamine therapy protocols carried out by licensed providers involve clinical screening to evaluate medical, psychiatric, and substance use history. Ketamine is not appropriate for everyone. Common contraindications include uncontrolled hypertension, active psychotic disorders, active substance use disorders, pregnancy, and certain cardiac or respiratory conditions. Comprehensive medical screening before treatment is a core component of responsible ketamine therapy across all three categories. The rigor of screening and ongoing safety monitoring varies more by provider than by category; reputable programs in any category conduct structured intake and ongoing monitoring throughout the treatment course.

Mindbloom Outcomes for Anxiety

The published data on Mindbloom's at-home sublingual ketamine therapy program for anxiety comes from two independent peer-reviewed studies in the Journal of Affective Disorders.¹,²

Mathai et al. 2024, the larger of the two studies, examined outcomes in 11,441 patients enrolled in Mindbloom's program, 7,776 of whom had a baseline GAD-7 score and 3,348 of whom had a session-4 GAD-7 score available for paired analysis.² Among patients with paired baseline and session-4 measurements:

• Mean GAD-7 score fell from 15.2 (moderate-to-severe anxiety) to 7.6 (mild anxiety) over 4 weeks, a 50% mean reduction.
• 56.1% of patients met response criteria, defined as a 50% or greater reduction in GAD-7 score.
• 28.8% of patients achieved remission, defined as a GAD-7 score below 5.
• The within-group effect size on the GAD-7 was Cohen's d = 1.46, a large effect by conventional thresholds.
• 0.4% of patients had GAD-7 scores increase, meaning measured anxiety worsening across the cohort was rare.

Hull et al. 2022 examined outcomes in 1,247 patients enrolled in the same program in an earlier cohort, 937 of whom had baseline GAD-7 scores.¹ Among patients with paired baseline and session-4 GAD-7 measurements:

• Mean GAD-7 fell from 14.8 to 7.1 over 4 weeks, a 52% mean reduction.
• 62.9% of patients met response criteria.
• 31.3% of patients achieved remission.
• The within-group effect size was Cohen's d = 1.56.

Across both studies combined, the published peer-reviewed evidence base for Mindbloom's program on anxiety covers more than 8,700 patients with structured baseline GAD-7 measurements.¹,² Based on the peer-reviewed literature available as of publication, this is the largest published anxiety effectiveness dataset for any ketamine therapy program.

A note on what this kind of study can and can't tell you. These are real-world effectiveness outcomes, not the results of a randomized controlled trial. The patients enrolled in Mindbloom's program were not selected for being treatment-refractory, and the studies were not designed with a placebo arm.¹,² That study design establishes scale and consistency across thousands of patients in real-world practice. It does not produce the clean drug-versus-placebo effect estimate that a randomized trial would.

Which Ketamine Therapy Option Is Right for Your Anxiety?

Choosing between ketamine therapy options for anxiety involves factors beyond what the published evidence shows. Cost, insurance coverage, geographic access, medical considerations identified during clinical screening, and personal preference about treatment setting all play a role. Those are properly worked out between a patient and a licensed provider during the screening and intake process.

When the evaluation criterion is what has actually been studied for anxiety in published peer-reviewed research, the comparison resolves more clearly.

• At-home therapeutic-dose ketamine therapy is the only category that has been studied for anxiety at scale in real-world clinical practice. The published outcomes describe a 50% mean reduction in GAD-7 anxiety scores and a 56–63% response rate across more than 8,700 patients in two peer-reviewed studies.¹,²
• In-clinic ketamine therapy has a published anxiety evidence base limited to small academic pilots (combined enrollment of around 50 patients) reporting favorable acute response, plus Spravato, which is not FDA-approved for any anxiety condition.⁴,⁶,⁷,⁸,¹¹ Because Spravato is restricted to REMS-certified settings and requires a qualifying depression diagnosis, there is no clinical pathway to access it as a stand-alone treatment for anxiety.¹¹
• Daily low-dose ketamine has no identifiable published prospective anxiety evidence in any population, on any schedule, at any duration.³ The protocol some providers market as a treatment for anxiety has not been studied for anxiety in the published literature.

On the criterion of published peer-reviewed evidence for anxiety specifically, at-home therapeutic-dose ketamine therapy is the only option that can point to effectiveness data at scale. Based on the peer-reviewed literature available as of publication, Mindbloom is the only at-home ketamine therapy program with effectiveness data published on its own patient population.¹,² If you are evaluating at-home ketamine therapy options for anxiety, the published outcomes data is one of several factors worth weighing alongside cost, screening rigor, ongoing clinical support, and your provider's experience with anxiety care.